AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 SAPPHIRE trials, according to a pooled analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC. While most patients experienced some adverse events, serious side effects were rare and few people discontinued treatment early for this reason.
Programs to promote appropriate use of antibiotics in hospitals and other healthcare facilities can help reduce use of these drugs and thereby ameliorate the risk of developing resistance, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.
Cal Cohen of the Community Research Initiative of New England sat down with HIVandHepstitis.com to offer his summary of some of the highlights of HIV treatment and prevention research presented at the 20th International AIDS Conference last month in Melbourne, Australia.
HIV positive natural controllers who maintain undetectable or low viral load without antiretroviral therapy (ART) are more likely to achieve adequate response to hepatitis B virus (HBV) vaccination and have improved survival, according to a study published in the August 21 edition of the open-access journal PLoS ONE.